Patents Assigned to Genetics Institute, LLC
-
Patent number: 7585646Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.Type: GrantFiled: December 17, 2004Date of Patent: September 8, 2009Assignee: Genetics Institute, LLCInventors: Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Patent number: 7576178Abstract: Polynucleotides encoding DADD protein are also disclosed, along with vectors, host cells, and methods of making DADD protein. Methods of identifying inhibitors of DADD death domain binding and inhibitors identified by such methods are also disclosed.Type: GrantFiled: May 13, 2005Date of Patent: August 18, 2009Assignee: Genetics Institute, LLCInventors: Jean-Baptiste Telliez, Lih-Ling Lin
-
Patent number: 7569669Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.Type: GrantFiled: July 6, 2006Date of Patent: August 4, 2009Assignee: Genetics Institute, LLCInventors: Simon Jones, Jin Tang
-
Publication number: 20090191147Abstract: The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.Type: ApplicationFiled: August 27, 2008Publication date: July 30, 2009Applicant: Genetics Institute, LLCInventors: James Keith, Joseph M. Carroll, Jordan S. Pober
-
Patent number: 7563760Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: GrantFiled: August 21, 2001Date of Patent: July 21, 2009Assignee: Genetics Institute, LLCInventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Patent number: 7553487Abstract: The present invention is directed to methods for treating asthma.Type: GrantFiled: November 15, 2004Date of Patent: June 30, 2009Assignees: Genetics Institute, LLC, The Johns Hopkins UniversityInventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew J. Whitters, Clive Wood, Marsha Wills-Karp
-
Publication number: 20090155836Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: October 22, 2008Publication date: June 18, 2009Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, GENETICS INSTITUTE, LLC, The United States of America as Represented by the Secretary of the NavyInventors: Carl H. JUNE, Craig B. THOMPSON, Gary J. NABEL, Gary S. GRAY, Paul D. RENNERT
-
Publication number: 20090148427Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.Type: ApplicationFiled: October 21, 2008Publication date: June 11, 2009Applicant: Genetics Institute, LLCInventors: Gray D. Shaw, Dianne S. Sako, Ravindra Kumar, Francis Sullivan, Tom McDonagh
-
Patent number: 7534430Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: September 28, 2006Date of Patent: May 19, 2009Assignee: Genetics Institute, LLCInventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 7531175Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: November 12, 2004Date of Patent: May 12, 2009Assignee: Genetics Institute LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 7531168Abstract: The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents that specifically block CD28-mediated signaling are provided. The subject methods are useful for both prophylactic and therapeutic downmodulation of immune responses.Type: GrantFiled: February 15, 2002Date of Patent: May 12, 2009Assignee: Genetics Institute LLCInventors: Richard M. O'Hara, Jr., AnnMarie Nagelin
-
Patent number: 7521532Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 12, 2002Date of Patent: April 21, 2009Assignee: Genetics Institute, LLCInventors: Kyriaki Dunussi-Joannopoulos, Vincent Ling
-
Publication number: 20090098132Abstract: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: September 23, 2008Publication date: April 16, 2009Applicants: Wyeth, Genetics Institute, LLCInventors: Margot O'Toole, William Martin Mounts, Negin Shojaee
-
Patent number: 7507706Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.Type: GrantFiled: December 13, 1999Date of Patent: March 24, 2009Assignee: Genetics Institute, LLCInventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew J. Whitters, Clive Wood, Marsha Wills-Karp
-
Publication number: 20090075884Abstract: Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.Type: ApplicationFiled: July 17, 2008Publication date: March 19, 2009Applicant: GENETICS INSTITUTE, LLCInventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
-
Patent number: 7479269Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 5, 2006Date of Patent: January 20, 2009Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7459544Abstract: Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO:1 or FIG. 14, SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.Type: GrantFiled: May 2, 2003Date of Patent: December 2, 2008Assignees: Genetics Institute, LLC, Dana-Farber Cancer InstituteInventors: Gordon J. Freeman, Lee M. Nadler, Gary S. Gray
-
Patent number: 7460961Abstract: The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein (“N-TRADD”), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provided for by the present invention are methods of utilizing the three dimensional structures for the design and selection of potent and selective inhibitors of TNF signaling pathways.Type: GrantFiled: July 20, 2004Date of Patent: December 2, 2008Assignee: Genetics Institute, LLCInventors: Desiree H. H. Tsao, Jean-Baptiste Telliez, Thomas McDonagh, Lih-Ling Lin, Sang Hsu, Guang-Yi Xu, A. Karl Malakian
-
Patent number: 7459533Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.Type: GrantFiled: December 17, 2004Date of Patent: December 2, 2008Assignee: Genetics Institute, LLC.Inventors: Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Patent number: 7432059Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 28, 2001Date of Patent: October 7, 2008Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC, Brigham and Women's HospitalInventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood, Yvette Latchman, Arlene H. Sharpe